EGFR and lung carcinoma: Dual targeting of EGFR and Notch3 may have a greater impact on inhibiting TKI-resistant lung cancer cell xenograft growth than focusing on either pathway alone, and the transcription factor p300/CBP contains an acetyltransferase domain that directly interacts with Notch3 via modulation of acetylation to promote degradation of Notch3 (44), so P300/CBP levels may be a useful mechanism-related marker of Notch3 activity in these patients.